Since its launch in March, Apple’s iOS-based platform ResearchKit has been largely successful. Now, ResearchKit adds autism, melanoma and epilepsy apps to help the medical community and patients alike.
Part of Apple’s efforts to prop medical community efforts in tracking, monitoring and timely delivering diagnoses and treatments for a wide array of health conditions, ResearchKit is largely successful. Conventional clinical trials are time and resource-consuming. With ResearchKit, part of the resource expense is cut. Moreover, the added benefit comes with the large amount of data generated directly by patients or Apple device users through the variety of apps already built on the iOS-based platform.
Streamlining a trove of data ranging from demographic to medical in just a matter of days after the initial five ResearchKit apps and studies were launched was a measure of success.
Now, ResearchKit adds autism, melanoma and epilepsy apps to upend the medical community’s efforts and provide numerous benefits to patients.
The autism trial started with the Autism&Beyond app is developed with the help of researchers from Duke University. Autism is a difficult to establish diagnosis. Diagnoses range from when a child is 18 months old to when he or she reaches the age of 5. However, it is estimated that 1 in every 68 children is affected by autism.
With the Autism&Beyond app included on the ResearchKit platform the researchers will be able to map how a child reacts to a list of approved stimuli. The children’s reactions, carefully evaluated may be linked to signs of autism. By providing this link, as well as creating a database of reactions and possible diagnoses, the researchers hope to be able to eventually create an application that would be handy in recognizing the symptoms and diagnose. Autism&Beyond is set for launch in South Africa and the U.S.
A second app, MoleMapper is integrated on ResearchKit with the help of Oregon Health and Science University. Much like other apps, its purpose is to help researchers create a database with images and other data generated by users on a monthly basis.
Melanoma is a type of skin cancer that may lead to death if left unchecked. During the past three decades, two times more cases of melanoma have been registered. 9,000 patients with melanoma die every year due to the disease. As such, an app that can deliver accurate prevention and early detection is welcome.
The third app, developed with the help of researchers from the John Hopkins University is titled EpiWatch.
According to statistics released by the World Health Organization, 50 million people across the globe are affected by epilepsy. The most dangerous epileptic episodes occur with those patients who do not follow treatment for the neurological disease. They represent about 40 percent of the patients worldwide.
EpiWatch is meant to follow the density of epileptic episodes, as well as specific information on them, collected directly from the patients.
Photo Credits: redmondpie.com
Latest posts by Christina Langfold (see all)
- Scientists Discover the Second Fastest Spinning Pulsar In The Universe - Sep 9, 2017
- Coral Reef Damage Scares Florida Keys Researchers and Businesses - Jun 26, 2017
- Nike to Slash Global Workforce by 1,400 - Jun 16, 2017